## Rules of
Department of Insurance, Financial Institutions and Professional Registration
Division 2220—State Board of Pharmacy
Chapter 6—Pharmaceutical Care Standards

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 CSR 2220-6.030 Provision of Drug and/or Medical Information</td>
<td>3</td>
</tr>
<tr>
<td>20 CSR 2220-6.040 Administration by Medical Prescription Order</td>
<td>3</td>
</tr>
<tr>
<td>20 CSR 2220-6.050 Administration of Vaccines Per Protocol</td>
<td>4</td>
</tr>
<tr>
<td>20 CSR 2220-6.055 Non-Dispensing Activities</td>
<td>5</td>
</tr>
<tr>
<td>20 CSR 2220-6.060 General Provisions</td>
<td>6</td>
</tr>
<tr>
<td>20 CSR 2220-6.070 Certificate of Medication Therapeutic Plan Authority</td>
<td>7</td>
</tr>
<tr>
<td>20 CSR 2220-6.080 Medication Therapy Services By Protocol</td>
<td>7</td>
</tr>
<tr>
<td>20 CSR 2220-6.100 Pharmacy Standards for Dispensing Blood-Clotting Products</td>
<td>10</td>
</tr>
</tbody>
</table>
Title 20—DEPARTMENT OF INSURANCE, FINANCIAL INSTITUTIONS AND PROFESSIONAL REGISTRATION
Division 2220—State Board of Pharmacy
Chapter 6—Pharmaceutical Care Standards

20 CSR 2220-6.030 Provision of Drug and/or Medical Information

PURPOSE: The purpose of this rule is to define requirements for the provision of drug and/or medical information by pharmacists.

(1) Section 338.095.3., RSMo provides in part that a pharmacist may lawfully provide prescription or medical information to a licensed health care provider or his/her agent who is legally qualified to administer medications and treatments and who is involved in the treatment of the patient. The information may be derived through direct contact with a prescriber or through a written, agreed upon protocol or standing prescription order from an authorized prescriber.

(2) Information transfers as described in section (1) may take place within any practice setting as long as the pharmacist maintains an active license with the Board of Pharmacy.

(3) Information transfers between two (2) licensed pharmacists may occur as long as the pharmacist receiving that information documents in a uniform and readily retrievable fashion, the identity of the pharmacist providing the information transfer, the origin of his/her authority to provide the drug or medical information, the date and the identity of the receiving pharmacist.

(4) When a transfer of prescription information for the purpose of filling an original prescription occurs, all provisions of 4 CSR 220-2.120 must be followed, except for subsection (1)(C) and paragraphs (2)(B)4.–6.

(5) Any laws governing prescription records, dispensing procedures and controlled substances must be adhered to when a transfer of prescription information for the purpose of filling an original prescription occurs.


20 CSR 2220-6.040 Administration by Medical Prescription Order

PURPOSE: This rule establishes procedures for pharmacists to administer medication pursuant to a medical prescription order.

(1) A pharmacist who complies with the provisions of this rule may administer drugs and devices pursuant to a medical prescription order, including vaccines.

(2) Except as otherwise provided by law, a pharmacist may not delegate medication administration to another person, except to an intern pharmacist who has met the qualifications under subsections (3)(B)–(E) and is working under the direct supervision of a pharmacist who has met the qualifications to administer drugs pursuant to a medical prescription order. Proof of an intern’s compliance with subsections (3)(B)–(E) must be maintained by both the supervising pharmacist and the intern pharmacist for a minimum of two (2) years.

(3) Pharmacist Qualifications. A pharmacist who is administering drugs pursuant to a medical prescription order must first file a Notification of Intent to administer drugs by medical prescription order with the board. To file a Notification of Intent, a pharmacist must—

(A) Hold a current Missouri pharmacist license;

(B) Hold a current healthcare provider level cardiopulmonary resuscitation (CPR) certification or Basic Life Support certification issued by the American Heart Association, the American Red Cross, or an equivalent organization. The certificate program must have included an in-person skills assessment;

(C) Have successfully completed a certificate program in medication administration and emergency procedures accredited by the Accreditation Council for Pharmacy Education (ACPE), provided by an ACPE or regionally accredited pharmacy or medical school/college or approved by the Board of Pharmacy. The required training program must provide instruction in—

1. Administration techniques, including hands-on training in routes of administration;
2. Drug storage and handling;
3. Informed consent requirements;
4. Pre- and post- administration assessment and counseling;
5. Biohazard waste disposal; and
6. Identifying and treating adverse reactions, including anaphylactic reactions and needle sticks;

(D) If a pharmacist wishes to administer drugs by a route of administration not included in the original certification program, the pharmacist must first be trained in the techniques of that route of administration by a licensed health care practitioner who is authorized to administer medication. Documentation of the required training and training date(s) must be maintained at the pharmacy and available to the board on request; and

(E) Proof of compliance with this section must be maintained for a minimum of two (2) years.

(4) General Requirements.

(A) Medication must be administered in compliance with all applicable state and federal laws, including applicable Vaccine Information Statements and informed consent requirements. Except as otherwise authorized by law, vaccines must also be administered in accordance with treatment guidelines established by the Centers for Disease Control and Prevention (CDC) or in accordance with manufacturer’s guidelines.

(B) Pharmacists must have a current and accurate written policy and procedure manual covering all aspects of administering drugs by medical prescription order, including:

1. Drug administration procedures;
2. Authorized routes of administration;
3. Drug storage;
4. Pre- and post- administration assessment and counseling;
5. Biohazard waste disposal and disposal of used/contaminated supplies;
6. Identifying and handling acute adverse events or immunization reactions, including anaphylactic reactions; and

7. Recordkeeping and notification procedures and requirements.

(C) Drugs must be stored within the manufacturer’s labeled requirements, including when administering outside of a pharmacy. Vaccines must be stored in accordance with CDC guidelines at all times.

(D) Patients must be asked to remain in the pharmacy a safe amount of time after administering a vaccine to observe any adverse reactions, as required by section 338.010, RSMo.

(5) Requirements of Medical Prescription Order for Administration. At a minimum, the medical prescription order from a licensed prescriber must include:

(A) The name of the licensed prescriber issuing or authorizing the order;

(B) The name of the patient to receive the
(C) The name of the drug and dose to be administered;

(D) The route of administration;

(E) The date of the original order; and

(F) The date or schedule, if any, of each subsequent administration.

(6) Record Keeping.

(A) Pharmacists administering or supervising administration of medication pursuant to this rule shall ensure the following records are manually or electronically maintained separate from the prescription files of a pharmacy for each administration:

1. The name, address, and date of birth of the patient;

2. The date, route, and anatomic site of the administration;

3. The medication name and dose. For vaccines and biologics, the manufacturer, expiration date, and lot number must also be documented and recorded;

4. For vaccines, the name and address of the patient’s primary health care provider, as identified by the patient or an indication that a primary health care provider was not provided;

5. The identity of the administering pharmacist, or if applicable, the administering intern pharmacist and his/her supervising pharmacist; and

6. If applicable, the nature of an adverse reaction and who was notified.

(B) All records required by this regulation must be kept by the pharmacist for two (2) years from the date of such record. Except as otherwise required by section (3), records must be kept at the pharmacy where the prescription order is maintained. If not administered on behalf of a pharmacy, records not maintained at a pharmacy may be securely stored at a location designated by the pharmacist. Records maintained at a pharmacy must be produced immediately or within two (2) hours of a request from the board or the board’s authorized designee.

(7) Notification Requirements. Pharmacists administering or supervising administration of medication under this rule, shall ensure:

(A) The patient’s primary health care provider, if provided by the patient, is notified of the following within fourteen (14) days of administering a vaccine:

1. The identity of the patient;

2. The vaccine administered;

3. The route of administration;

4. The anatomic site of the administration;

5. The dose administered; and

6. The date of administration;

(B) The prescriber is notified within twenty-four (24) hours after learning of an adverse event or reaction experienced by a patient following administration. Notification is mandatory and cannot be waived;

(C) Any notifications required by state and federal law are properly completed and documented; and

(D) Notifications required by this section may be made electronically or in writing or via a common electronic medication record that is accessible to and shared by both the physician and pharmacist. Documentation of the required notifications, including the notification date, must be maintained as required by subsection (6)(B) or electronically retrievable at the request of the board or the board’s authorized designee.

(8) Notification of Intent Refiling. To continue administration, a Notification of Intent to administer drugs by medical prescription order must be refiled with the board biennially along with the pharmacist’s Missouri pharmacist license. To refile, a pharmacist must meet the requirements of subsection (3)(B) above.


20 CSR 2220-6.050 Administration of Vaccines Per Protocol

PURPOSE: This rule establishes the procedures for pharmacists to administer vaccines per written protocol with a physician.

(1) A pharmacist may administer vaccines authorized by Chapter 338, RSMo, pursuant to a written protocol authorized by a physician licensed pursuant to Chapter 334, RSMo, who is actively engaged in the practice of medicine.

(A) A pharmacist shall administer vaccines in accordance with treatment guidelines established by the Centers for Disease Control (CDC) and in accordance with manufacturer’s guidelines, provided that a pharmacist shall not administer vaccines to persons under twelve (12) years of age.

(B) A pharmacist shall comply with all state and federal laws and regulations pertaining to Vaccine Information Statements and informed consent requirements.

(2) A pharmacist may not delegate the administration of vaccines to another person, except to a pharmacist intern who has met the qualifications under subsections (4)(B), (C), and (D) and is working under the direct supervision of a pharmacist qualified to administer vaccines.

(3) The authorizing physician is responsible for the oversight of, and accepts responsibility for, the vaccines administered by the pharmacist.

(4) Pharmacist Qualifications. A pharmacist who is administering a vaccine authorized by Chapter 338, RSMo, must:

(A) Hold a current, unrestricted license to practice pharmacy in this state;

(B) Hold a current cardiopulmonary resuscitation (CPR) certification issued by the American Heart Association or the American Red Cross or equivalent;

(C) Successfully complete a certificate program in the administration of vaccines accredited by the Accreditation Council for Pharmacy Education (ACPE) or a similar health authority or professional body approved by the State Board of Pharmacy;

(D) Maintain documentation of the above certifications;

(E) Complete a minimum of two (2) hours (0.2 CEU) of continuing education as defined per calendar year related to administration of vaccines. A pharmacist may use the continuing education hours required in this subsection as part of the total continuing education hours required for pharmacist license renewal;

(F) Provide documentation of subsections (A), (B), (C), and (E) of this section to the authorizing physician(s) prior to entering into a protocol or administering vaccines; and

(G) On a yearly basis prior to administering vaccines, establish a new protocol with the authorizing physician and notify the State Board of Pharmacy of their qualifications to do so. This notification shall include the types of drugs being administered and a statement that the pharmacist meets the requirements of subsections (A), (B), (C), (E), and (F) of this section.

(5) Administration by Written Protocol with a Missouri Licensed Physician.

(A) A pharmacist may enter into a written
protocol with a physician for the administration of vaccines authorized by Chapter 338, RSMo, provided that a pharmacist shall be prohibited from administering vaccines to patients under twelve (12) years of age. The physician must be no further than fifty (50) miles by road, using the most direct route available, from the pharmacist who is administering the vaccine. The written protocol may be valid for a time period not to exceed one (1) year. The protocol must include the following:

1. The identity of the participating pharmacist and physician, including signatures;
2. Time period of the protocol;
3. The identification of the vaccines which may be administered;
4. The identity of the patient or groups of patients to receive the authorized vaccine(s);
5. The identity of the authorized routes and anatomic sites of administration allowed;
6. A provision to create a prescription for each administration under the authorizing physician’s name;
7. A provision establishing a course of action the pharmacist shall follow to address emergency situations including, but not limited to, adverse reactions, anaphylactic reactions, and accidental needle sticks;
8. A provision establishing a length of time the pharmacist shall observe an individual for adverse events following an injection;
9. A provision establishing the disposal of used and contaminated supplies;
10. The street addresses of the pharmacy or other locations at which the pharmacist may administer the authorized vaccine;
11. Record-keeping requirements and procedures for notification of administration; and
12. A provision that allows for termination of the protocol at the request of any party to it at any time.

(B) The protocol, and any subsequent amendments or alterations, shall be signed and dated by the pharmacist and authorizing physician prior to its implementation, signifying that both are aware of its content and agree to follow the terms of the protocol. The authorizing physician and pharmacist shall each maintain a copy of the protocol from the beginning of implementation to a minimum of eight (8) years after termination of the protocol.

(6) Record Keeping.

(A) A pharmacist administering vaccines pursuant to this rule shall maintain a record of each administration which shall include:

1. The name, address, and date of birth of the patient;
2. The date, route, and anatomic site of the administration;
3. The name, dose, manufacturer, lot number, and expiration date of the vaccine;
4. The name and address of the patient’s primary health care provider, as identified by the patient;
5. The name or identifiable initials of the authorizing pharmacist; and
6. The nature of an adverse reaction and who was notified, if applicable.

(B) If the vaccine was administered on behalf of a pharmacy, the pharmacist shall ensure the records required by subsection (6)(A) of this rule are promptly delivered to the pharmacy.

(C) Within seventy-two hours (72) hours after administration of a vaccine, the administering pharmacist shall obtain a prescription from the authorizing physician for the drug dispensed or shall create a prescription, as authorized by protocol documenting the dispensing of the drug. Notwithstanding any other provision of this rule, prescription records shall be maintained as provided by Chapter 338, RSMo, and the rules of the board.

(D) The records required by this rule shall be maintained securely and confidentially as follows:

1. If the vaccine is administered on behalf of a pharmacy, both the pharmacy and the authorizing pharmacist shall ensure that all records required by this rule are maintained at the pharmacy separate from the prescription files of the pharmacy. If the vaccine is not being administered on behalf of a pharmacy, all records shall be maintained securely and confidentially by the authorizing pharmacist at an address that shall be identified in the protocol prior to administering the vaccine; and
2. Records shall be maintained for two (2) years from the date of such record and shall be made available for inspecting and copying by the State Board of Pharmacy or the State Board of Registration for the Healing Arts and/or their authorized representatives. Records maintained at a pharmacy must be produced during an inspection by the board and/or their authorized representatives. Records not maintained at a pharmacy shall be produced within three (3) business days after a request from the State Board of Pharmacy and/or its authorized representative. Failure to maintain or produce records as provided by this rule shall constitute grounds for discipline.

(7) Notification Requirement.

(A) A pharmacist administering vaccines authorized by Chapter 338, RSMo, shall notify the authorizing physician within seventy-two (72) hours after administration of the following:

1. The identity of the patient;
2. The identity of the vaccine(s) administered;
3. The route of administration;
4. The anatomic site of the administration;
5. The dose administered; and
6. The date of administration.

(B) The pharmacist shall provide a written report to the patient’s primary health care provider, if different than the authorizing physician, containing the documentation required in subsection (A) of this section within fourteen (14) days of the administration.

(C) In the event of any adverse event or reaction experienced by the patient pursuant to a written protocol, the pharmacist shall notify the patient’s primary health care provider and authorizing physician, if different, within twenty-four (24) hours after learning of the adverse event or reaction.

(D) A pharmacist administering vaccine(s) shall report the administration to all entities as required by state or federal law.

(E) Documentation that notifications required by this rule have been sent must be maintained as provided in section (6) of this rule.


20 CSR 2220-6.055 Non-DISPENSING Activities

PURPOSE: This rule establishes procedures and requirements for the performance of non-dispensing activities outside of a pharmacy.

(1) Pursuant to section 338.220, RSMo, a pharmacist may perform the following non-dispensing activities outside of a licensed pharmacy:

(A) Patient counseling/education, as authorized by Missouri law, provided the pharmacist shall be obligated to comply with 20 CSR 2220-2.190, when applicable;
(B) Obtain patient history/information;
(C) Review patient records/medical histories;
(D) Patient assessment/evaluation, as authorized by Missouri law;
(E) Billing and insurance claim submissions/review;
(F) Drug utilization review;
(G) Assess health plan and medication eligibility/coverage;
(H) Pharmacy compliance audits/evaluations;
(I) Administer drugs, vaccines, or biologicals, as authorized by law and the rules of the board;
(J) Peer review/peer consultations;
(K) Review, select, and develop formularies or plan/practice guidelines;
(L) Review compliance with benefit guidelines;
(M) Manage inventory, including purchasing and ordering;
(N) Manage/review information systems;
(O) Patient medication review;
(P) Consultation with other health care professionals;
(R) Prescription order entry/review, provided that a pharmacist shall only be authorized to accept a prescription on the premises of a Missouri licensed pharmacy, as required by section 338.095.5, RSMo; and
(S) Medication therapy management, pursuant to and as authorized by Chapter 338, RSMo, and the rules of the board.

(2) Confidentiality. A pharmacist performing non-dispensing activities pursuant to this rule shall comply with all applicable state and federal confidentiality laws and regulations and shall provide sufficient storage and security for confidential documents and electronic data processing hardware. In addition, data processing systems must utilize sufficient security software to ensure confidentiality and prevent unauthorized access. Any breach in the security or confidentiality of the data processing systems or confidential documents shall be documented and reported to the board in writing within seven (7) days of the breach.

(3) Notwithstanding any other provision of this rule, a pharmacist shall not meet with patients in the pharmacist’s residence or living quarters.

(4) A pharmacist performing non-dispensing activities pursuant to this rule shall ensure compliance with Chapter 338, RSMo, and the rules of the board at all times. Nothing in this rule shall be construed to eliminate or otherwise exempt any pharmacist from the record-keeping, confidentiality, or security requirements otherwise imposed by Chapter 338, RSMo, or the rules of the board. Violations of this section shall constitute grounds for discipline.

(5) This rule shall not be construed to authorize a pharmacist to conduct the unauthorized practice of medicine or to conduct any activity for which a license is required pursuant to Chapters 330, 331, 332, 334, or 337, RSMo.

(6) A pharmacy permit shall be required for performing non-dispensing activities if the pharmacist is using a pharmacy technician to assist in the practice of pharmacy at the location where non-dispensing activities are being performed, provided that a pharmacy permit shall not be required for sites used solely by the pharmacist for administering vaccines as authorized by Chapter 338, RSMo, and the rules of the board. Pharmacy technicians shall only be authorized to work under the direct supervision of a pharmacist as provided by section 338.013, RSMo, and 20 CSR 2220-2.700.


20 CSR 2220-6.060 General Provisions

PURPOSE: This rule establishes definitions for 20 CSR 2220-6.060 to 20 CSR 2220-6.080 governing medication therapy services by pharmacists.

(1) Definitions. The following definitions shall apply for purposes of 20 CSR 2220-6.060 to 20 CSR 2220-6.080:

(A) Authorizing physician(s)—The physician identified in the written protocol as authorizing the pharmacist to provide medication therapy services;

(B) Health care entity—For purposes of this rule, a health care entity shall be defined as any entity or organization that is licensed or certified by the state or federal government as a hospital, hospice facility, ambulatory surgical center, nursing home, long-term care facility, residential care facility, assisted living facility, intermediate care facility, skilled nursing facility, or a habilitation center as defined by Chapter 338, RSMo, and that is required to maintain patient medical records by state or federal law;

(C) Medication therapy protocol—A written agreement between a physician and a pharmacist for the provision of medication therapy services. A medication therapy protocol shall comply with the provisions of 20 CSR 2220-6.080;

(D) Medication therapy services—The designing, initiating, implementing, or monitoring of a plan to monitor the medication therapy or device usage of a specific patient, or to enhance medication therapeutic outcomes of a specific patient, by a pharmacist who has authority to initiate or implement a modification of the patient’s medication therapy or device usage pursuant to a medication therapy protocol. For purposes of 20 CSR 2220-6.060 to 20 CSR 2220-6.080, modification shall include selecting a new, different, or additional medication or device, discontinuing a current medication or device, or selecting a new, different, or additional strength, dose, dosage form, dosage schedule, or route of administration for a current medication or device, and implementing such selection(s). Medication therapy services shall not include the sole act of dispensing a drug or device pursuant to a valid prescription for the product, generic substitutions made pursuant to section 338.056, RSMo, or medication therapy management that does not include the initiation or implementation of a modification of medication therapy, as provided herein;

(E) Pharmacy resident—A Missouri-licensed pharmacist enrolled in a residency training program accredited by the American Society of Health-System Pharmacists or a residency training program with a valid application for accreditation pending with the American Society of Health-System Pharmacists;

(F) Prescription order for medication therapeutic plan—A lawful order that is issued by the authorizing physician within the scope of his/her professional practice for the provision of medication therapy services by a pharmacist for a specific patient, including, patients of a health care entity; and

(G) Protocol—A medication therapy protocol, as defined herein.

(2) The provisions of 20 CSR 2220-6.060 to 20 CSR 2220-6.080 and 20 CSR 2150-5.026 to 20 CSR 2150-5.028 shall only be deemed applicable to persons or entities under the jurisdiction of the Missouri State Board of Pharmacy and the Missouri State Board of Registration for the Healing Arts, as established by Chapter 338, RSMo, and Chapter
PURPOSE: This rule establishes procedures for obtaining a certificate of medication therapeutic plan authority, as authorized by section 338.010, RSMo.

(1) A pharmacist shall obtain a certificate of medication therapeutic authority from the Missouri State Board of Pharmacy to provide medication therapy services that include initiating or implementing a modification of a patient’s medication therapy or device usage. Pharmacist with a certificate of medication therapeutic authority shall enter into a written protocol with a Missouri-licensed physician that complies with the requirements of 20 CSR 2220-6.080, prior to performing medication therapy services.

(2) Applicants for certification shall hold an active Missouri pharmacist license. Applications shall be submitted on forms provided by the Missouri State Board of Pharmacy and shall be accompanied by the certificate of medication therapeutic plan authority fee and shall be accompanied by the certificate of medication therapeutic plan authority if the Missouri State Board of Pharmacy and license shall be earned in courses/programs accredited or granted by the Missouri State Board of Pharmacy to provide medication therapeutic plan authority from the board governing medication therapy services.

(3) Certificate Renewal. A certificate of medication therapeutic plan authority shall be renewed biennially with the certificate holder’s Missouri pharmacist license. For purposes of renewal, six (6) of the continuing education hours required for renewing the certificate holder’s Missouri pharmacist license shall be earned in courses/programs related to medication therapy management. The continuing education required by this rule shall be governed by the rules of the Missouri State Board of Pharmacy governing pharmacist continuing education.

(4) The Missouri State Board of Pharmacy may discipline or terminate a pharmacist’s certificate of medication therapeutic plan authority if the Missouri State Board of Pharmacy determines that the pharmacist has violated the terms of a protocol, the requirements of Chapter 338, RSMo., or rules of the board governing medication therapy services or any other state or federal drug law.


20 CSR 2220-6.080 Medication Therapy Services By Protocol

PURPOSE: This rule establishes procedures for the provision of medication therapy services by protocol, as authorized by section 338.010, RSMo.

(1) Except as otherwise provided herein, a pharmacist who holds a certificate of medication therapeutic plan authority from the Missouri State Board of Pharmacy shall be authorized to provide medication therapy services in Missouri if the pharmacist—

(A) Holds a current Missouri pharmacist license that is not under discipline with the Missouri State Board of Pharmacy; and

(B) Has entered into a written protocol with a Missouri licensed physician that complies with the requirements of this rule.

(2) General Requirements. A pharmacist may provide medication therapy services only with current certification and as authorized by the protocol and the authorizing physician. A pharmacist providing medication therapy services pursuant to this rule shall comply with the following:

(A) Prior to providing medication therapy services, the pharmacist shall receive a prescription order for a medication therapeutic plan from the authorizing physician for a specific patient which authorizes the pharmacist to perform medication therapy services. Except as otherwise provided in subsection (2)(B) of this rule, the prescription order for a medication therapeutic plan shall be valid for no more than one (1) year and shall include:

1. The patient’s name, address, and date of birth;

2. The date the prescription order for a medication therapeutic plan is issued;

3. The clinical indication for medication therapy services;

4. The length of time for providing medication therapy services, if less than one (1) year; and

5. The authorizing physician’s name and address;

(B) A prescription order for a medication therapeutic plan may be transmitted orally, electronically, or in writing. If an oral prescription order for a medication therapeutic plan is issued, all information required under subsection (2)(A) of this rule shall be documented by the pharmacist and maintained in the patient’s record in accordance with section (7) of this rule;

(C) The pharmacist shall review relevant prescription records, patient profiles, patient medical records, or other medical information to determine the services to be rendered; and

(D) In lieu of compliance with 20 CSR 2220-2.018, prescription orders for medication therapy services shall comply with the
provisions of this rule, provided the pharmacist shall maintain the prescription order in the patient record required by section (7) of this rule and shall document any change or alteration made to the prescription ordered based on contact with the prescriber in the applicable patient record.

(3) Authorizing Physician Requirements.

(A) The authorizing physician shall be actively engaged in the practice of medicine in the state of Missouri and shall hold a current and unrestricted Missouri physician license pursuant to Chapter 334, RSMo.

(B) The authorizing physician shall be responsible for the oversight of the medication therapy services provided by the pharmacist that are authorized by protocol. The authorizing physician shall also consider the level of skill, education, training, and competence of the pharmacist and ensure that the activities authorized by the protocol are consistent with the pharmacist’s level of skill, education, training, and competence.

(C) The written protocol shall be reviewed and signed by the pharmacist and the authorizing physician at least annually and revised as needed. The authorizing physician and pharmacist shall document the date of the annual review on the written protocol.

(D) The authorizing physician shall review the pharmacist’s medication therapy service activities regularly, but not less than once every three (3) months. If the pharmacist is providing medication therapy services for, or on behalf of, a health care entity, the review requirements shall be satisfied if the pharmacist’s work and services are reviewed every three (3) months by a clinical care committee, pharmacy and therapeutics committee, or a reviewing body/committee of the health care entity that includes a Missouri-licensed physician. The review required by this subsection may be accomplished in person or by electronic means.

(E) The practice location of the authorizing physician shall be no further than fifty (50) miles by road from the pharmacist identified in the written protocol.

(F) An authorizing physician shall notify the Missouri State Board of Registration for the Healing Arts of a written protocol for medication therapy services entered with a pharmacist at each renewal of the authorizing physician’s license.

(4) Protocol Requirements.

(A) The medication therapy services performed by a pharmacist pursuant to the protocol shall be within the authorizing physician’s scope of practice and within the skill, education, training, and competence of both the authorizing physician and the pharmacist.

(B) The written protocol between the authorizing physician and pharmacist shall, at a minimum, include the following:

1. The identity and signatures of the authorizing physician and pharmacist;
2. The effective dates of the protocol;
3. A statement of clinical conditions, diagnoses, diseases, and specific drugs, or drug categories included in the written protocol and the type of medication therapy services allowed in each case;
4. A statement of the methods, procedures, decision criteria, and plan the pharmacist is to follow when conducting medication therapy services;
5. Procedures for documenting medication therapy decisions made by the pharmacist and a plan for communication, feedback, and reporting to the authorizing physician concerning specific decisions made;
6. A mechanism and procedure that allows the authorizing physician to override, rescind, modify, or otherwise amend the protocol. All modifications or amendments to the protocol shall be documented in writing, signed, and dated by all involved parties prior to the implementation of such modification or amendment. The protocol may be immediately rescinded by the authorizing physician or the pharmacist with or without cause, provided the rescission is documented in writing. If any conflict arises regarding the professional judgment of the pharmacist and physician with regard to the subject of the medication therapy services, the physician has ultimate authority;
7. A statement that the pharmacist shall not delegate the responsibility of medication therapy services to another person;
8. A description of any authority granted to the pharmacist to administer any drug or medication including the identification of any such drug, medication, or device;
9. A description of drug therapy related patient assessment procedures or testing that may be ordered or performed by the pharmacist, including any authority to order or perform routine or other laboratory testing;
10. Provisions for allowing the pharmacist to access the patient’s medical records for purposes of providing medication therapy services;
11. A provision for providing the authorizing physician access to patient records for medication therapy services provided by the pharmacist for patients of the authorizing physician;
12. Provisions establishing a course of action the pharmacist is authorized to follow to address emergency situations, including, but not limited to, anaphylactic or other adverse medication reactions, adverse needle sticks, or other adverse events;
13. Criteria for timely communication from the authorizing physician to the pharmacist and from the pharmacist to the authorizing physician, not inconsistent with the provisions of this rule;
14. The notification requirements required by section (5) of this rule; and
15. The method for reviewing the pharmacist’s medication therapy work or services by the authorizing physician, as required by subsection (3)(D) of this rule.

(C) The written protocol shall include a description of medication therapy services the pharmacist is authorized to render or provide. Such services may include:

1. Assessing patient-specific data and issues;
2. Establishing medication therapeutic goals or medication related action plans for identified medical conditions and medication related concerns;
3. Assessing and addressing adverse reactions and adverse drug events;
4. Modifying and monitoring medication regimens;
5. Evaluating treatment progress;
6. Assessing and monitoring pharmacokinetic and pharmacodynamic changes in medication regimen reviews;
7. Medication reconciliation;
8. Drug utilization review;
9. Formulating and documenting personal medication records;
10. Documenting clinical outcomes;
11. Interpreting, monitoring, and assessing patient test results;
12. Initiation of drug therapy, as authorized by protocol; and
13. Patient education and counseling.

(D) The protocol required by this section shall be signed and dated by the authorizing physician and the pharmacist. If the protocol includes multiple authorizing physicians or participating pharmacists, a separate protocol shall not be required for each physician or pharmacist if all authorizing physicians and pharmacists have signed and dated a statement agreeing to be governed by the terms of the written protocol.

(E) Any revisions, modifications, or amendments to the protocol must be in writing. The authorizing physician shall promptly notify the pharmacist of any such revision, modification, or amendment and shall maintain documentation of the notification, including the date such notification was made. The authorizing physician may delegate the notification requirements of this subsection to an authorized designee, provided the physician shall be ultimately responsible
for compliance with the notification requirements.

(F) A pharmacist shall not be authorized to adjust, change, or modify any controlled substance prescribed for a patient, except as authorized by state or federal law.

(G) The protocol shall be maintained by the authorizing physician and the pharmacist for a minimum of eight (8) years after termination of the protocol. The protocol may be maintained electronically.

(H) A protocol shall automatically and immediately terminate if the pharmacist ceases to maintain an active Missouri pharmacist license, the authorizing physician is deceased, or if the authorizing physician fails to maintain an active, unrestricted Missouri physician license.

(I) Pharmacy Residents. If specifically authorized by the protocol, a pharmacy resident shall be authorized to perform medication therapy services under the written protocol of a Missouri pharmacist in lieu of an individual protocol, if—

1. The resident holds a certificate of medication therapeutic plan authority from the Missouri State Board of Pharmacy;
2. The resident is enrolled in a residency training program accredited by the American Society of Health-System Pharmacists or a residency training program with a valid application for accreditation pending with the American Society of Health-System Pharmacists; and
3. The resident is providing medication therapy services under the supervision of a Missouri pharmacist certified by the Missouri State Board of Pharmacy to perform medication therapy services.

(J) The provisions of subsection (4)(I) shall only apply to medication therapy services provided by a pharmacist as part of his/her residency training.

(5) Notification Requirements. A pharmacist shall comply with the following notification requirements:

(A) Within twenty-four (24) hours after learning of an anaphylactic or other adverse medication reaction, adverse needle stick, or other adverse event experienced by a patient, the pharmacist shall notify the patient's authorizing physician or an authorized designee of the authorizing physician;

(B) The pharmacist shall notify the authorizing physician or an authorized designee of the authorizing physician in the written protocol of any modification of therapy, within twenty-four (24) hours, provided the protocol may include more stringent notification requirements;

(C) A pharmacist shall be deemed in compliance with the notification requirements of this rule if the pharmacist is providing medication therapy services for, or on behalf of, a health care entity, as defined by this rule, and documentation of the notifications required by this section is recorded in a patient medical record that is required to be maintained by the health care entity pursuant to state or federal law; and

(D) Notifications required by this section shall be in writing unless otherwise authorized by the authorizing physician.

(6) Modifying Drug Therapy.

(A) A pharmacist may be authorized by protocol to modify a patient's non-controlled substance medication therapy, subject to the following:

1. If the pharmacist modifies medication therapy and a medication or device is to be dispensed, the pharmacist shall create a prescription for the medication or device modified under the authorizing physician’s name. Such prescription may be dispensed by a licensed pharmacy and shall be maintained in the prescription records of the dispensing pharmacy as provided by the rules of the Missouri State Board of Pharmacy; and
2. If the pharmacist modifies medication therapy or a device, the pharmacist shall document such modification according to section (7) of this rule. Pharmacists providing medication therapy services for patients of a health care entity shall be deemed in compliance with the provisions of this subsection if the modification is documented in a patient medical record that the health care entity is required to maintain under state or federal law.

(B) The pharmacist shall not modify any controlled substance prescription. A prescription from the authorizing physician shall be required to modify a controlled substance.

(C) For purposes of 20 CSR 2220-6.060, 20 CSR 2220-6.070, and 20 CSR 2220-6.080, modification of medication therapy shall include selecting a new, different, or additional medication or device, discontinuing a current medication or device, or selecting a new, different, or additional strength, dose, dosage form, dosage schedule, or route of administration for a current medication or device, and implementing such selection(s). Medication therapy services shall not include the sole act of dispensing a drug or device pursuant to a valid prescription for the product or generic substitutions made pursuant to section 338.056, RSMo.

(7) Record Keeping.

(A) A pharmacist shall document and maintain an adequate patient record of medication therapy services provided to each patient. The records may be maintained in electronic format provided the records are capable of being printed for review by the Missouri State Board of Registration for the Healing Arts and the Missouri State Board of Pharmacy. An adequate and complete patient record shall include documentation of the following:

1. The identification of the patient, including name, birthdate, address, and telephone number;
2. The date(s) of any patient visit or consultation, including the reason for any such visit/consultation;
3. Any pertinent assessments, observations, or findings;
4. Any informed consent for procedures, medications, or devices; and
5. Any consultation with any other treatment provider for the patient and the results of such consultation.

(B) Pharmacist Record Retention. Except as otherwise provided herein, records required to be maintained by a pharmacist pursuant to this rule shall be maintained securely and confidentially for a minimum of seven (7) years after termination of the protocol unless more stringent requirements are established for record keeping under state or federal law. All records required to be maintained by the pharmacist by this rule shall be maintained by the pharmacist at an address that shall be identified in the written protocol.

(C) Physician Record Retention. Except as otherwise provided herein, records required to be maintained by the authorizing physician pursuant to this rule shall be maintained securely and confidentially for a minimum of seven (7) years after termination of the protocol unless more stringent requirements are established for record keeping pursuant to state or federal law.

(8) Production of Records. Records maintained at a pharmacy must be produced during an inspection or investigation by the Missouri State Board of Pharmacy, Missouri
20 CSR 2220-6.100 Pharmacy Standards for Dispensing Blood-Clotting Products

PURPOSE: This rule implements the provisions of section 338.400, RSMo, and establishes pharmacy standards for dispensing blood-clotting products.

(1) Definitions. The following definitions are hereby adopted and applicable to this rule:

(A) “Bleeding disorder,” a medical condition characterized by a deficiency or absence of one (1) or more essential blood-clotting components in the human blood, including all forms of hemophilia, acquired hemophilia, von Willebrand’s disease, and other bleeding disorders that result in uncontrollable bleeding or abnormal blood-clotting. As defined by section 338.400, RSMo, “bleeding disorder” does not include a bleeding condition secondary to another medical condition or diagnosis, except for acquired hemophilia;

(B) “Blood-clotting product,” a medicine approved for distribution by the federal Food and Drug Administration (FDA) that is used for the treatment and prevention of symptoms associated with bleeding disorders, including, but not limited to, recombinant and plasma derived factor products, von Willebrand factor products, antifibrinolytics, bypass products for patients with inhibitors, prothrombin complex concentrates, and activated prothrombin complex concentrates. Except as otherwise provided by section 338.400, RSMo, a “blood-clotting product” does not include medical products approved solely for the treatment or prevention of side effects of a blood-clotting drug or medication;

(C) “Established patient,” For purposes of this rule or the provisions of a written protocol, an “established patient” shall be defined as a patient’s designee pursuant to subsection (2)(E);

(D) “Pharmacy,” an entity engaged in the practice of pharmacy as defined in section 338.100, RSMo, that provides blood-clotting factor concentrates, prothrombin complexes, and activated prothrombin complex concentrates, and activated prothrombin complex concentrates. Except as otherwise provided by section 338.400, RSMo, a “blood-clotting product” does not include medical products approved solely for the treatment or prevention of side effects of a blood-clotting drug or medication;

(E) “Pharmacy,” an entity engaged in the practice of pharmacy as defined in section 338.100, RSMo, that provides blood-clotting products and ancillary infusion equipment or supplies to patients with bleeding disorders.

(2) General Requirements. All Missouri licensed pharmacists and pharmacy permit holders shall comply with the following requirements when dispensing blood-clotting factor concentrates:

(A) Prescriptions for blood-clotting factor concentrates shall be dispensed as written or authorized by the prescribing physician, in accordance with state and federal law. No changes or substitutions shall be made unless approved by the prescriber. If the pharmacy has received prescriber authorization to change or substitute the blood-clotting factor concentrate originally prescribed, the patient or the patient’s designee shall be notified and counseled regarding the change or substitution prior to dispensing via the preferred contact method identified by the patient or designee pursuant to subsection (2)(E);

(B) If requested by the patient or the patient’s designee, the pharmacy shall ship and deliver blood-clotting factor concentrates to the patient or the patient’s designee as prescribed within two (2) business days of receiving a prescription or refill request for established patients and three (3) business days for new patients in nonemergency situations. Nonemergency situations shall include, but may not be limited to, routine prophylaxis requests. Appropriate cold chain management and packaging practices must be used to ensure proper drug temperature, stability, integrity, and efficacy are maintained during shipment in accordance with manufacturer requirements;

(C) Patients must be provided with a designated pharmacy contact telephone number for reporting problems with a delivery or product on each dispensing at no cost to the patient;

(D) Unless otherwise authorized by the patient or the patient’s designee, the pharmacy shall contact the patient for authorization to dispense prior to shipping a refill of any blood-clotting product to the patient. The date of patient authorization shall be documented in the pharmacy’s prescription records;

(E) Barring extenuating circumstances, prescriptions for blood clotting factor concentrates shall be dispensed within plus or minus ten percent (10%) of prescribed assays, or as otherwise authorized or directed by the prescriber; and

(F) Recalls or Withdrawals. Prior to dispensing any blood clotting factor concentrate, the pharmacy shall ask the patient or the patient’s designee to designate a preferred contact method for receiving notifications in the event of a recall or withdrawal of the concentrate dispensed or any related ancillary infusion equipment and supplies dispensed by the pharmacy. The preferred contact method shall be documented with the patient information required by 20 CSR 2220-2.190(2).

1. Notice of concentrate or ancillary infusion equipment and supplies recalls and withdrawals shall be provided to the patient via the patient’s preferred contact method within twenty-four (24) hours of receipt of a recall or withdrawal notification from the manufacturer or any state or federal entity.
that requires or recommends patient notification. The pharmacy shall also notify the prescribing physician within twenty-four (24) hours of such recall or withdrawal and shall obtain a prescription for an alternative product if a new or amended prescription is required to dispense or deemed necessary and appropriate by the prescriber.

2. If attempts to contact the patient via the preferred contact method are unsuccessful, the pharmacy shall mail notification to the patient or the patient’s authorized designee within the required twenty-four (24) hours or the next business day.

3. The time, date, and method of notification to the patient and prescriber shall be documented in the pharmacy’s records and maintained for two (2) years from the date of recall or withdrawal.

(3) In addition to the provisions of section (2), pharmacies that dispense blood-clotting products to established patients, or that offer or advertise to provide blood-clotting products specifically for bleeding disorder patients, shall comply with the following standards of care:

(A) The pharmacy shall annually notify the board in writing of the pharmacy’s intent to provide legend blood-clotting products for bleeding disorder patients. Notification shall be made on or before January 31 of each calendar year in a manner and form approved by the board;

(B) The pharmacy shall identify in advance, or make arrangements with, a supplier or suppliers capable of providing all brands, assays, and vial sizes of blood-clotting products approved by the federal FDA, including products manufactured from human plasma and those manufactured from recombinant technology techniques. A list of all designated or identified suppliers shall be maintained at the pharmacy and made available during inspection. This requirement shall not be construed to require a pharmacy to purchase products prior to receiving a valid prescription order;

(C) A pharmacist shall be available twenty-four (24) hours a day, seven (7) days a week, every day of the year, either on-site or on-call, to fill prescriptions for blood-clotting products, within the time frames designated by section 338.400, RSMo, and the provisions of this rule;

(D) Pharmacists engaged in dispensing or filling blood-clotting factor concentrates or who provide patient counseling regarding blood-clotting factor concentrates to bleeding disorder patients shall have sufficient knowledge, experience, and training to perform the duties assigned. To ensure continued competency, pharmacists engaged in counseling bleeding disorder patients shall complete four (4) continuing education hours (0.40 CEU) related to blood-clotting factor concentrates, infusion treatment or therapy, or blood-clotting disorders or diseases each biennial renewal period. The continuing education required by this rule may be used to satisfy the pharmacist’s continuing education requirements. Proof of compliance with this section shall be maintained at the pharmacy for a minimum of four (4) calendar years and shall be made available during inspection or at the request of the board;

(E) If requested by the patient or the patient’s designee, the pharmacy shall provide for the shipment and delivery of blood-clotting products to the patient or the patient’s designee as prescribed within two (2) business days of receiving a prescription or refill request for established patients and three (3) business days for new patients in nonemergency situations;

(F) Established patients shall be provided access to blood-clotting products within twelve (12) hours of notification from a physician of the patient’s emergent need for a blood-clotting product. For purposes of this section, determination of an emergent need shall be within the professional medical judgment of the physician. Emergent need requests shall be documented in the pharmacy’s prescription records;

(G) The pharmacy shall provide or have available for purchase containers for the disposal of hazardous waste, including, but not limited to, sharp or equivalent biohazard waste containers;

(H) At a minimum, the pharmacy shall provide or have available for purchase ancillary equipment and supplies required to infuse a blood-clotting therapy product into a human vein, including, syringes, needles, sterile gauze, field pads, gloves, alcohol swabs, numbing creams, tourniquets, medical tape, and cold compression packs. If supplies are depleted, the pharmacy shall restock the required ancillary equipment and supplies in a reasonable amount of time which shall not exceed seven (7) calendar days;

(I) The pharmacy shall have contact information available for a nurse or nursing service or agency with experience in providing infusion related nursing services or nursing services for bleeding disorder patients if such services are not provided by the pharmacy;

(J) If requested by the patient or the patient’s authorized designee, the pharmacist shall explain any known insurance copayments, deductibles, coinsurance payments, or lifetime maximum insurance payment limits. For purposes of complying with this section, the pharmacy may rely on information supplied by the patient’s insurer; and

(K) The pharmacy shall register with the National Patient Notification System, or its successor, to receive recall notification for all products included in the National Patient Notification System. The pharmacy shall maintain current and accurate contact information with the National Patient Notification System.

(4) Pharmacies that provide legend blood-clotting products to treat or prevent symptoms of established bleeding disorder patients, or that offer or advertise to provide blood-clotting products specifically for bleeding disorder patients, shall develop and follow written policies and procedures to ensure compliance with section 338.400, RSMo, and the provisions of this rule. The pharmacy shall review the policies and procedures on an annual basis and document such review. At a minimum, the pharmacy’s written policies and procedures must include procedures for:

(A) Processing prescriptions for blood-clotting products by pharmacy staff to ensure the timely handling and dispensing of blood-clotting products;

(B) Processing partial fill requests by patients to reduce or eliminate excessive dispensing;

(C) Providing and documenting recall notifications in accordance with this rule;

(D) Transferring, dispensing, refilling, or delivering blood-clotting factor concentrates to established patients in the event of an emergency or disaster;

(E) Notifying patients prior to terminating business or terminating the dispensing of any blood-clotting factor concentrate or prior to a known or an anticipated termination of pharmacy services for a bleeding disorder patient. Notification shall be provided in writing and, when reasonably possible, shall be provided a minimum of seven (7) days prior to any such termination;

(F) Shipping or providing blood-clotting products to the patient within the time frames required herein;

(G) Receiving, processing, and dispensing prescription or dispensing requests for a blood-clotting product to bleeding disorder patients, including procedures for handling and processing physician request indicating a patient’s emergent need for a blood-clotting product;

(H) Ensuring appropriate cold chain management and packaging practices are used to ensure proper drug temperature, stability, integrity, and efficacy are maintained during shipment in accordance with manufacturer requirements; and
(I) Handling and processing preauthorization notifications and requests and communicating preauthorization requirements to the patient and applicable prescriber.

(5) This rule shall not be construed to require dispensing without appropriate payment or payment arrangements. If the pharmacy is waiting for authorization, certification, or other action from a third-party payer prior to dispensing, the pharmacy shall notify the patient that the prescription is available for dispensing and explain any alternative payment options. Notification shall be provided as soon as reasonably practicable. At a minimum, however, notification shall be provided to the patient prior to the expiration of the shipping and delivery time frames required by subsection (2)(E), (3)(B), or (3)(F) of this rule.
